Benzinga
Benzinga
Benzinga
lunes, septiembre 21

Cardlytics Inc

CDLXNASDAQ
Trade with Public
Trade with Public
$3.75
-0.14-3.6%
al cierre: Sep 18, 5:00 PM EST
$3.75
N/A
After hour: Sep 18, 4:00 PM EST
Panorámica generalNoticiasPrevisión de beneficiosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Cardlytics Financials

Cardlytics (CDLX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Cardlytics Sees Q3 Sales $34.000M-$39.000M vs $38.594M Est

Cardlytics (NASDAQ:CDLX) sees Q3 sales of $34.000 million-$39.000 million vs $38.594 million analyst estimate.
Benzinga Newsdesk

PRO
Cardlytics Q2 Adj. EPS $(0.81) Beats $(1.35) Estimate, Sales $36.882M Miss $37.003M Estimate

Benzinga Newsdesk

PRO
Cardlytics Sees Q2 Sales $35.000M-$40.000M vs $37.519M Est

Cardlytics (NASDAQ:CDLX) sees Q2 sales of $35.000 million-$40.000 million vs $37.519 million analyst estimate.
Benzinga Newsdesk

PRO
Cardlytics Q1 Adj. EPS $(0.11) Beats $(0.21) Estimate, Sales $34.319M Miss $37.200M Estimate

Cardlytics (NASDAQ:CDLX) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.21) by 47.62 percent. This is a 47.62 percent increase over losses of $(0.21) per share from the
Benzinga Newsdesk

Cardlytics Q4 Earnings Assessment

Benzinga Insights

PRO
Cardlytics Sees Q1 Sales $35.000M-$40.000M vs $48.695M Est

Cardlytics (NASDAQ:CDLX) sees Q1 sales of $35.000 million-$40.000 million vs $48.695 million analyst estimate.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved